MetaVia’s tiny Phase 1 obesity study just posted 13.5% weight loss and a 68% liver-fat reduction. How much can investors trust yet?
MetaVia’s DA-1726 cut weight 13.5% and liver fat 68% versus placebo at 16 weeks, but the Phase 1 dataset includes just 19 participants.